Maladies dans Onco Wiki
OpenOnco coverage across 103 oncology diagnoses: biomarkers, drugs, indications/regimens/RedFlags, algorithm and questionnaire presence, fill and optional recorded content-review evidence.
Définitions métriques
- #Bio — biomarqueurs distincts référencés par les indications + régimes de cette maladie
- Drogue — médicaments distincts dans les régimes de cette maladie
- #Ind / #Reg / #RF — Indications / Régimes / RedFlags pour cette maladie
- 1L / 2L — Algorithm presence for first-line / second-line+
- Quête — ✓ artisans / STUB autogénérés / — absents
- Remplir % — composite over 8 entity types: ≥1 indication, ≥1 regimen, ≥1 biomarker, ≥1 drug, ≥1 redflag, 1L algo, questionnaire, workup
- Vert % — % of this disease's indications with reviewer_signoffs ≥ 2 (CHARTER §6.1)
Projet individuel. Une personne responsable publie les mises à jour avec des contrôles automatisés et des sources traçables. La relecture clinique externe est facultative et consignée séparément.
Total des maladies
103
Remplir la cavité aviaire
69.8%
Avec algorithme 1L
87/103
Avec algorithme 2L+
55/103
103
No diseases match your search.
Couverture de la maladie
Lymphoïde hématologique (28)
| Maladie | ICD-10 | Bio | Médicament | End | Régulation | RF | 1L | 2L | Quête | Remplir % | Vert % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ATLL Leucémie/lymphome T de l’adulte | C91.5 | 1 | 9 | 5 | 3 | 8 | ✓ | ✓ | — | 88% | 0% |
| ALCL Lymphome anaplasique de grandes cellules, systémique | C84.6 | 2 | 6 | 5 | 5 | 5 | ✓ | ✓ | — | 88% | 0% |
| AITL Lymphome angioimmunoblastique T-Cell | C84.4 | 2 | 9 | 5 | 5 | 8 | ✓ | ✓ | — | 88% | 0% |
| B-ALL Leucémie lymphoblastique B/Lymphome | C91.0 | 1 | 14 | 8 | 5 | 9 | ✓ | ✓ | — | 88% | 0% |
| BURKITT Lymphome de Burkitt | C83.7 | 3 | 15 | 10 | 6 | 10 | ✓ | ✓ | — | 88% | 0% |
| CLL Leucémie lymphocytaire chronique / Petit lymphome lymphoytique | C91.1 | 5 | 7 | 8 | 6 | 13 | ✓ | ✓ | ✓ | 88% | 0% |
| CHL Lymphome classique de Hodgkin | C81.9 | 3 | 7 | 7 | 5 | 6 | ✓ | ✓ | — | 88% | 0% |
| DLBCL-NOS Lymphome diffus à grandes cellules B, sans autre précision | C83.3 | 8 | 15 | 26 | 10 | 23 | ✓ | ✓ | — | 88% | 0% |
| NK-T-NASAL Lymphome extranodal NK/T-Cell, type nasal | C86.0 | 1 | 8 | 3 | 3 | 5 | ✓ | ✓ | — | 88% | 0% |
| FL Lymphome folliculaire | C82.0 | 3 | 12 | 9 | 8 | 9 | ✓ | ✓ | — | 88% | 0% |
| HCV-MZL Lymphome de zone marginale associé au VHC | C88.4 | 1 | 3 | 7 | 3 | 7 | ✓ | ✓ | ✓ | 88% | 0% |
| HGBL-DH Lymphome B de haut grade, double-hit / triple-hit | C83.3 | 5 | 8 | 3 | 3 | 7 | ✓ | ✓ | — | 88% | 0% |
| MCL Lymphome cellulaire du manteau | C83.1 | 5 | 12 | 7 | 6 | 9 | ✓ | ✓ | — | 88% | 0% |
| MM Myélome multiple | C90.0 | 2 | 13 | 16 | 13 | 14 | ✓ | ✓ | ✓ | 88% | 0% |
| MF-SEZARY Mycose Fungoides / Syndrome de Sézary | C84.0 | 1 | 3 | 5 | 4 | 5 | ✓ | ✓ | — | 88% | 0% |
| NODAL-MZL Lymphome de zone marginale nodale | C83.0 | 3 | 3 | 4 | 3 | 5 | ✓ | ✓ | — | 88% | 0% |
| NLPBL Lymphome nodulaire prédominant des cellules B | C81.0 | 1 | 5 | 3 | 2 | 6 | ✓ | ✓ | — | 88% | 0% |
| PTLD Trouble lymphoprolifératif post-transplantation | D47.Z1 | 3 | 5 | 3 | 3 | 6 | ✓ | ✓ | — | 88% | 0% |
| PCNSL Lymphome primaire du SNC | C85.7 | 1 | 6 | 3 | 3 | 6 | ✓ | ✓ | — | 88% | 0% |
| PMBCL Lymphome principal médiastinal Grand lymphome B-Cell | C85.2 | 1 | 8 | 3 | 3 | 8 | ✓ | ✓ | — | 88% | 0% |
| SPLENIC-MZL Lymphome de la zone marginale splénique | C83.0 | 3 | 3 | 3 | 3 | 5 | ✓ | ✓ | — | 88% | 0% |
| T-PLL T-Cell Leucémie prolymphocytaire | C91.6 | 1 | 2 | 2 | 2 | 5 | ✓ | ✓ | — | 88% | 0% |
| WM Waldenström Macroglobulinémie / Lymphome lymphoplasmacytique | C88.0 | 2 | 6 | 5 | 5 | 7 | ✓ | ✓ | — | 88% | 0% |
| EATL Lymphome entéropathique associé aux cellules T | C86.2 | 0 | 7 | 4 | 2 | 6 | ✓ | — | — | 75% | 0% |
| HCL Leucémie à cellules poilues | C91.4 | 0 | 2 | 3 | 2 | 5 | ✓ | ✓ | — | 75% | 0% |
| HSTCL Lymphome hépatosplenique T-Cell | C84.7 | 0 | 7 | 2 | 2 | 6 | ✓ | — | — | 75% | 0% |
| PTCL-NOS Lymphome T-cellulaire périphérique, NOS | C84.4 | 0 | 8 | 4 | 4 | 5 | ✓ | ✓ | — | 75% | 0% |
| T-ALL Leucémie/Lymphome T-Lymphoblastique | C91.0 | 0 | 9 | 2 | 2 | 9 | ✓ | ✓ | — | 75% | 0% |
| avg | 85.7% | 0.0% | |||||||||
Hématologie myéloïde (9)
| Maladie | ICD-10 | Bio | Médicament | End | Régulation | RF | 1L | 2L | Quête | Remplir % | Vert % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AML Leucémie aiguë myéloïde | C92.0 | 4 | 13 | 39 | 10 | 37 | ✓ | ✓ | — | 88% | 0% |
| MASTOCYTOSIS Mastocytose systémique avancée | C96.2, D47.09 | 1 | 2 | 2 | 2 | 6 | ✓ | — | — | 88% | 0% |
| PV Polycythémie Vera | D45 | 1 | 5 | 6 | 4 | 6 | ✓ | ✓ | — | 88% | 0% |
| APL Leucémie promyélocytique aiguë | C92.4 | 0 | 4 | 4 | 4 | 9 | ✓ | ✓ | — | 75% | 0% |
| CML Leucémie myéloïde chronique | C92.1 | 0 | 7 | 5 | 5 | 9 | ✓ | ✓ | — | 75% | 0% |
| ET Thrombocythémie essentielle | D47.3 | 0 | 3 | 3 | 2 | 7 | ✓ | ✓ | — | 75% | 0% |
| MDS-HR Syndromes myélodysplasiques — Risque plus élevé | D46.2 | 0 | 2 | 7 | 3 | 15 | ✓ | ✓ | — | 75% | 0% |
| MDS-LR Syndromes myélodysplasiques — Risque réduit | D46.9 | 0 | 4 | 4 | 4 | 9 | ✓ | ✓ | — | 75% | 0% |
| PMF Myélofibrose primaire | D47.4 | 0 | 3 | 5 | 4 | 7 | ✓ | ✓ | — | 75% | 0% |
| avg | 79.3% | 0.0% | |||||||||
Tumeurs solides (66)
| Maladie | ICD-10 | Bio | Médicament | End | Régulation | RF | 1L | 2L | Quête | Remplir % | Vert % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| THYROID-ANAPLASTIC Carcinome thyroïdien anaplasique | C73 | 1 | 4 | 2 | 2 | 7 | ✓ | — | — | 88% | 0% |
| BCC Carcinome à cellules basales | C44 | 2 | 2 | 4 | 2 | 8 | ✓ | — | — | 88% | 0% |
| CERVICAL Carcinome cervical | C53 | 2 | 7 | 9 | 4 | 17 | ✓ | — | — | 88% | 0% |
| CHOLANGIOCARCINOMA Cholangiocarcinome | C22.1, C24.0 | 3 | 9 | 12 | 8 | 10 | ✓ | ✓ | — | 88% | 0% |
| CRC Carcinome colorectal | C18-C20 | 5 | 16 | 75 | 15 | 43 | ✓ | ✓ | — | 88% | 0% |
| MELANOMA Mélanome cutané | C43 | 2 | 12 | 15 | 8 | 19 | ✓ | ✓ | — | 88% | 0% |
| ENDOMETRIAL Carcinome de l'endomètre | C54 | 2 | 5 | 9 | 4 | 23 | ✓ | ✓ | — | 88% | 0% |
| ESOPHAGEAL Carcinome de l'oesophage | C15 | 3 | 13 | 19 | 10 | 15 | ✓ | ✓ | — | 88% | 0% |
| GI-NET Tumeur neuroendocrine GI (carcinoïde) | C17.9 | 1 | 1 | 1 | 1 | 6 | ✓ | — | — | 88% | 0% |
| GASTRIC Adénocarcinome de jonction gastrique et gastro-œsophagienne | C16 | 5 | 18 | 19 | 9 | 25 | ✓ | ✓ | — | 88% | 0% |
| GIST Tumeur stromale gastro-intestinale | C49 | 2 | 4 | 4 | 4 | 6 | ✓ | ✓ | — | 88% | 0% |
| GBM Glioblastome | C71 | 2 | 2 | 6 | 4 | 8 | ✓ | ✓ | — | 88% | 0% |
| HNSCC Carcinome à cellules squamouses de la tête et du cou | C00-C14, C30-C32 | 1 | 6 | 9 | 5 | 9 | ✓ | ✓ | — | 88% | 0% |
| HCC Carcinome hépatocellulaire | C22.0 | 4 | 10 | 32 | 8 | 23 | ✓ | ✓ | — | 88% | 0% |
| IFS Fibrosarcome infantile | C49 | 1 | 1 | 1 | 1 | 5 | ✓ | — | — | 88% | 0% |
| IMT Tumeur myofibroblastique inflammatoire | D48.1 | 1 | 1 | 1 | 1 | 5 | ✓ | — | — | 88% | 0% |
| BREAST Cancer du sein invasif | C50 | 11 | 26 | 84 | 19 | 65 | ✓ | ✓ | — | 88% | 0% |
| GLIOMA-LOW-GRADE Gliome de bas grade | C71 | 1 | 3 | 9 | 1 | 11 | ✓ | — | — | 88% | 0% |
| LAM Lymphangioléiomyomatose | J84.81 | 1 | 1 | 1 | 1 | 1 | ✓ | — | — | 88% | 0% |
| MTC Carcinome thyroïdien médullaire | C73 | 1 | 2 | 6 | 2 | 8 | ✓ | — | — | 88% | 0% |
| NSCLC Cancer bronchique non à petites cellules | C34 | 19 | 32 | 77 | 30 | 44 | ✓ | ✓ | — | 88% | 0% |
| OVARIAN Carcinome ovarien | C56 | 4 | 11 | 25 | 11 | 34 | ✓ | ✓ | — | 88% | 0% |
| PDAC Adénocarcinome canalaire du pancréas | C25 | 1 | 9 | 18 | 5 | 36 | ✓ | ✓ | — | 88% | 0% |
| PNET Tumeur neuroendocrine pancréatique | C25.4 | 1 | 1 | 7 | 1 | 5 | ✓ | — | — | 88% | 0% |
| PROSTATE Adénocarcinome de la prostate | C61 | 4 | 10 | 9 | 8 | 27 | ✓ | ✓ | — | 88% | 0% |
| RCC Carcinome des cellules rénales | C64 | 1 | 7 | 27 | 7 | 23 | ✓ | ✓ | — | 88% | 0% |
| UROTHELIAL Carcinome urothelial | C67 | 1 | 6 | 16 | 6 | 20 | ✓ | ✓ | — | 88% | 0% |
| GRANULOSA-CELL Tumeur des cellules granuleuses adultes | C56 | 1 | 2 | 1 | 1 | 0 | ✓ | — | — | 75% | 0% |
| ANAL-SCC Carcinome à cellules squameuses anales (CSC anal) | C21.0 | 0 | 5 | 3 | 3 | 2 | ✓ | — | — | 75% | 0% |
| CHONDROSARCOMA Chondrosarcome | C40, C41 | 0 | 1 | 1 | 1 | 5 | ✓ | — | — | 75% | 0% |
| EPITHELIOID-SARCOMA Sarcome épithélioïde | C49 | 1 | 1 | 1 | 1 | 0 | ✓ | — | — | 75% | 0% |
| KAPOSI Sarcome de Kaposi | C46 | 1 | 4 | 11 | 4 | 4 | ✓ | — | — | 75% | 0% |
| LARYNGEAL Carcinome à cellules squameuses laryngées | C32 | 1 | 5 | 7 | 4 | 1 | ✓ | — | — | 75% | 0% |
| MESOTHELIOMA Mésothéliome maligne | C45.0 | 0 | 4 | 5 | 3 | 5 | ✓ | ✓ | — | 75% | 0% |
| MPNST Tumeur maligne de la gaine nerveuse périphérique | C47 | 0 | 2 | 1 | 1 | 6 | ✓ | — | — | 75% | 0% |
| THYROID-PAPILLARY Carcinome thyroïdien papillaire | C73 | 0 | 1 | 3 | 1 | 10 | ✓ | — | — | 75% | 0% |
| PARATHYROID-CARCINOMA Carcinome parathyroïdien | C75.0 | 2 | 2 | 3 | 2 | 1 | ✓ | — | — | 75% | 0% |
| PENILE-SCC Carcinome à cellules squameuses du pénis | C60 | 1 | 5 | 5 | 3 | 1 | ✓ | — | — | 75% | 0% |
| PITUITARY-ADENOMA Adénome de la pituitaire | D35.2 | 1 | 3 | 4 | 3 | 1 | ✓ | — | — | 75% | 0% |
| SALIVARY Carcinome de la glande salivaire | C07, C08 | 0 | 2 | 1 | 1 | 6 | ✓ | — | — | 75% | 0% |
| SCLC Cancer bronchique à petites cellules | C34 | 0 | 7 | 7 | 7 | 16 | ✓ | ✓ | — | 75% | 0% |
| SOFT-TISSUE-SARCOMA Sarcome des tissus mous | C49.9 | 0 | 6 | 10 | 4 | 8 | ✓ | ✓ | — | 75% | 0% |
| TGCT Tumeur de cellules géantes ténosynoviennes | M12.2 | 1 | 1 | 1 | 1 | 0 | ✓ | — | — | 75% | 0% |
| TESTICULAR-GCT Tumeur des cellules germinatives testiculaires | C62.9 | 2 | 5 | 4 | 3 | 0 | ✓ | ✓ | — | 75% | 0% |
| VULVAR-VAGINAL-SCC Carcinome de cellules squameuses et de la vulve | C51, C52 | 1 | 2 | 5 | 2 | 3 | ✓ | — | — | 75% | 0% |
| ADRENOCORTICAL-CARCINOMA Carcinome adrénocortical | C74.0 | 0 | 4 | 2 | 2 | 2 | ✓ | — | — | 62% | 0% |
| NPC Carcinome nasopharyngé | C11 | 0 | 3 | 2 | 2 | 1 | ✓ | — | — | 62% | 0% |
| PHEOCHROMOCYTOMA Phéochromocytome | D35.0 | 0 | 4 | 14 | 4 | 9 | ✓ | — | — | 62% | 0% |
| JMML Leucémie myélomonocytique juvénile | C93.3 | 0 | 0 | 1 | 1 | 0 | ✓ | — | — | 50% | 0% |
| MENINGIOMA Méningiome | D32 | 0 | 0 | 1 | 0 | 1 | ✓ | — | — | 50% | 0% |
| OSTEOSARCOMA Ostéosarcome | C40, C41 | 0 | 0 | 2 | 0 | 4 | — | — | — | 25% | 0% |
| WILMS Tumeur Wilms | C64 | 0 | 0 | 2 | 0 | 2 | — | — | — | 25% | 0% |
| LEIOMYOSARCOMA Leiomyosarcome | C49, C54.2 | 0 | 0 | 0 | 0 | 2 | — | — | — | 12% | 0% |
| ATRT Tératoïde atypique/tume rhabdoïde | C71.9 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| CHOROID-PLEXUS-CARCINOMA Carcinome du plexus choroid | C71.5 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| CYSTIC-NEPHROMA Néphrome kystique | D30.0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| HEPATOBLASTOMA Hépatoblastome | C22.2 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| MEDULLOBLASTOMA Médulloblastome | C71.6 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| NEUROBLASTOMA Neuroblastome | C74.9 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| PARAGANGLIOMA Paragangliome | D44.7 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| PINEOBLASTOMA Pineoblastome | C75.3 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| PITUITARY-BLASTOMA Blastome de la pituitaire | C75.1 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| PLEUROPULMONARY-BLASTOMA Blastome pleuropulmonaire | C34 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| RETINOBLASTOMA Rétinoblastome | C69.2 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| RHABDOMYOSARCOMA Le rhabdomyosarcome | C49.9 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| SERTOLI-LEYDIG-OVARIAN Tumeur des cellules Sertoli-Leydig | C56 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| avg | 61.7% | 0.0% | |||||||||